Late-breaking data show breadth of abbott's minimally invasive structural heart technologies

Five late-breaking presentations at tct 2022 highlight the impact of abbott's structural heart devices to repair or replace heart valves and close openings in the heart new data reinforce the safety and effectiveness of mitraclip™ for treating mitral regurgitation results also demonstrate the benefits of abbott's triclip™ for tricuspid regurgitation, amulet™ for stroke reduction in patients with atrial fibrillation and portico™ for aortic stenosis abbott park, ill., sept. 17, 2022 /prnewswire/ -- abbott (nyse: abt) today announced data from five late-breaking presentations showing the benefits of its minimally invasive devices in treating people with a range of structural heart diseases.
ABT Ratings Summary
ABT Quant Ranking